scholarly journals A Time-Based Meta-Analysis on the Incidence of New Onset Diabetes after Liver Transplantation

2021 ◽  
Vol 10 (5) ◽  
pp. 1045
Author(s):  
Yip Han Chin ◽  
Hon Qin Marcus Tan ◽  
Cheng Han Ng ◽  
Darren Jun Hao Tan ◽  
Snow Yunni Lin ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Transplant ◽  
Mixed Model ◽  
Linear Mixed Model ◽  
Meta Analysis ◽  
Summary Statistics ◽  
Important Complication ◽  
Onset Diabetes ◽  
One Year ◽  
New Onset

NODAT (new-onset diabetes after transplantation) is an important complication after liver transplant, however, there is variation in the reported incidence of NODAT. Therefore, a meta-analysis was performed to estimate the incidence of NODAT in liver transplant. Electronic databases were searched for articles regarding NODAT incidence after liver transplantation. Incidence of NODAT were analyzed at six different timepoints. Summary statistics were calculated using a generalized linear mixed model in random effects. 28 articles were included and out of a pooled population of 71,257 patients, overall incidence of NODAT was found to be 15.51%, 16.09%, 18.30%, 20.86%, 18.08%, 25.05% for three-months, six-months, one-year, three-year, five-year, and ten-year timepoints respectively. After a sensitivity analysis which only included articles with clear definitions of NODAT, the incidence of NODAT was found to be higher at three-year (21.79%), five-year (25.82%), and ten-year (44.95%) timepoints. Subgroup analysis according to ethnicity found no significant differences for all timepoints. However, studies with predominantly Asian participants generally had a higher incidence of NODAT. In conclusion, this meta-analysis provides a pooled estimate of the incidence of NODAT following liver transplantation. Further studies are required to provide a more comprehensive understanding on how ethnicity can affect the incidence of NODAT.

New-onset diabetes after liver transplantation: a national report from China Liver Transplant Registry

2016 ◽  
Vol 36 (5) ◽  
pp. 705-712 ◽  
Author(s):  
Qi Ling ◽  
Xiao Xu ◽  
Haiyang Xie ◽  
Kai Wang ◽  
Penghui Xiang ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Transplant ◽  
Onset Diabetes ◽  
National Report ◽  
Transplant Registry ◽  
New Onset

20 Post-Operative Biologics and the Rate of Recurrence in Crohn’s Disease

2021 ◽  
Vol 108 (Supplement_2) ◽  
Author(s):  
C H Ng ◽  
S R Jain ◽  
Z G W Ow ◽  
W H Lim ◽  
H Y Tham ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Mixed Model ◽  
Linear Mixed Model ◽  
Meta Analysis ◽  
Operative Management ◽  
Suitable Alternative ◽  
Significant Challenge ◽  
One Year ◽  
The One

Abstract Introduction Post-operative recurrence after Crohn’s surgery poses a significant challenge to clinicians with an estimated of 70-90% recurrence rate. However, with the advent of biologics, reduction of recurrence after surgery has been observed in various landmark trials. Hence, we aim to quantify the rate of recurrence with post-operative biologics. Method Searches were done on Embase and Medline database for articles using biologics for post-operative management. A single arm meta-analysis with generalized linear mixed model and Clopper-Pearson method confidence interval was applied in the synthesis of the data on six months, one year, two year and five year. Results A total of 1,864 abstracts were identified, with a final total of 24 articles and 1042 patients were included in the meta-analysis. The one-year rate of recurrence for surgical, endoscopic and clinical was 3.08% (CI: 0.74% - 11.95%), 19.93% (15.81% - 24.81%) and 13.06% (CI: 8.18% - 18.92%) respectively. Correspondingly, the five-year recurrence 16.90% (CI: 9.57% - 28.11%), 84.21% (CI: 72.35% - 91.57%), 5.60% (CI: 9.92% -23.66%) respectively. Conclusions An observed reduction in surgical rates was reduced at five years with post-operative Crohn’s disease with biologics. Biologics therapy thus can be considered as a suitable alternative for reducing post-operative recurrence in individuals with higher risk.

scholarly journals Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Elizabeth J. Carey ◽  
Bashar A. Aqel ◽  
Thomas J. Byrne ◽  
David D. Douglas ◽  
Jorge Rakela ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplant ◽  
Fasting Glucose ◽  
Meld Score ◽  
Transplant Recipients ◽  
Onset Diabetes ◽  
The Mean ◽  
One Year ◽  
Liver Transplant Recipients ◽  
New Onset

New-onset diabetes after transplantation (NODAT) is common after liver transplant and associated with poorer outcomes. The aim of this study was to identify risk factors for NODAT in liver transplant recipients off corticosteroids. In 225 adult nondiabetic liver transplant recipients, the mean age was 51.7 years, the majority were men (71%), and half had HCV (49%). The mean calculated MELD score at transplantation was 18.7, and 19% underwent living-donor transplant (LDLT). One year after transplantation, 17% developed NODAT, and an additional 16% had impaired fasting glucose. The incidence of NODAT in patients with HCV was 26%. In multivariate analysis, HCV, pretransplant FPG, and LDLT were significant. Each 10 mg/dL increase in pretransplant FPG was associated with a twofold increase in future development of NODAT. The incidence of NODAT after liver transplant in patients off corticosteroids is 17%. Risk factors for developing NODAT include HCV and pretransplant FPG; LDLT is protective.

scholarly journals Systematic Review and Meta-Analysis on the Impact of Thrombolytic Therapy in Liver Transplantation Following Donation after Circulatory Death

2018 ◽  
Vol 7 (11) ◽  
pp. 425 ◽  
Author(s):  
Kumar Jayant ◽  
Isabella Reccia ◽  
Francesco Virdis ◽  
A. Shapiro
Keyword(s):  
Liver Transplantation ◽  
Blood Transfusion ◽  
Graft Survival ◽  
Meta Analysis ◽  
Donation After Cardiac Death ◽  
Clinical Trial Registry ◽  
Increased Risk ◽  
Increasing Demand ◽  
One Year ◽  
The Impact

Aim: The livers from DCD (donation after cardiac death) donations are often envisaged as a possible option to bridge the gap between the availability and increasing demand of organs for liver transplantation. However, DCD livers possess a heightened risk for complications and represent a formidable management challenge. The aim of this study was to evaluate the effects of thrombolytic flush in DCD liver transplantation. Methods: An extensive search of the literature database was made on MEDLINE, EMBASE, Cochrane, Crossref, Scopus databases, and clinical trial registry on 20 September 2018 to assess the role of thrombolytic tissue plasminogen activator (tPA) flush in DCD liver transplantation. Results: A total of four studies with 249 patients in the tPA group and 178 patients in the non-tPA group were included. The pooled data revealed a significant decrease in ischemic-type biliary lesions (ITBLs) (P = 0.04), re-transplantation rate (P = 0.0001), and no increased requirement of blood transfusion (P = 0.16) with a better one year graft survival (P = 0.02). Conclusions: To recapitulate, tPA in DCD liver transplantation decreased the incidence of ITBLs, re-transplantation and markedly improved 1-year graft survival, without any increased risk for blood transfusion, hence it has potential to expand the boundaries of DCD liver transplantation.

Sign in / Sign up

Export Citation Format

Share Document